Revance Therapeutics | RVNC - Pre Tax Profit


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Revance Therapeutics

Revance Therapeutics reported $-59793000 in Pre-Tax Profit for its fiscal quarter ending in March of 2023.


Pre Tax Profit Change
AbbVie ABBV:US USD 5.08B 2.33B
Cara Therapeutics CARA:US USD -26665000 3.67M
Coherus Biosciences CHRS:US USD -75729000 16.86M
J&J JNJ:US USD 8.47B 1.05B
Merck & Co MRK:US USD 4.48B 411M
Neurocrine Biosciences NBIX:US USD -103300000 221.2M
P&G PG:US USD 4.29B 547M
Revance Therapeutics RVNC:US USD -59793000 86.16M
Supernus Pharmaceuticals SUPN:US USD 9.02M 26.12M